Bionano Genomics, Inc. (BNGO): Price and Financial Metrics

Bionano Genomics, Inc. (BNGO): $1.02

0.01 (+0.99%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add BNGO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#227 of 360

in industry

BNGO Price/Volume Stats

Current price $1.02 52-week high $11.80
Prev. close $1.01 52-week low $1.00
Day low $1.00 Volume 926,300
Day high $1.03 Avg. volume 1,679,432
50-day MA $1.24 Dividend yield N/A
200-day MA $2.99 Market Cap 55.79M

BNGO Stock Price Chart Interactive Chart >

BNGO POWR Grades

  • Value is the dimension where BNGO ranks best; there it ranks ahead of 61.32% of US stocks.
  • The strongest trend for BNGO is in Growth, which has been heading up over the past 26 weeks.
  • BNGO's current lowest rank is in the Stability metric (where it is better than 2.64% of US stocks).

BNGO Stock Summary

  • For BNGO, its debt to operating expenses ratio is greater than that reported by just 9.11% of US equities we're observing.
  • The volatility of BIONANO GENOMICS INC's share price is greater than that of 96.62% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BNGO comes in at -63.29% -- higher than that of just 6.63% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BIONANO GENOMICS INC are EMKR, VMAR, RCAT, TELL, and OPGN.
  • Visit BNGO's SEC page to see the company's official filings. To visit the company's web site, go to www.bionanogenomics.com.

BNGO Valuation Summary

  • In comparison to the median Healthcare stock, BNGO's price/sales ratio is 47.62% lower, now standing at 2.2.
  • Over the past 65 months, BNGO's EV/EBIT ratio has gone up 3.7.

Below are key valuation metrics over time for BNGO.

Stock Date P/S P/B P/E EV/EBIT
BNGO 2023-12-29 2.2 0.6 -0.3 -0.2
BNGO 2023-12-28 2.4 0.7 -0.4 -0.2
BNGO 2023-12-27 2.4 0.7 -0.4 -0.3
BNGO 2023-12-26 2.3 0.6 -0.3 -0.2
BNGO 2023-12-22 2.0 0.6 -0.3 -0.2
BNGO 2023-12-21 1.9 0.5 -0.3 -0.2

BNGO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BNGO has a Quality Grade of D, ranking ahead of 7.91% of graded US stocks.
  • BNGO's asset turnover comes in at 0.063 -- ranking 71st of 75 Measuring and Control Equipment stocks.
  • 500 - Internal server error

The table below shows BNGO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.063 0.333 -3.723
2021-03-31 0.082 0.336 -2.825
2020-12-31 0.230 0.326 -4.176
2020-09-30 0.248 0.369 -6.041
2020-06-30 0.352 0.344 -2.947
2020-03-31 0.402 0.312 -2.104

BNGO Price Target

For more insight on analysts targets of BNGO, see our BNGO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.50 Average Broker Recommendation 1.12 (Strong Buy)

Bionano Genomics, Inc. (BNGO) Company Bio


Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.


BNGO Latest News Stream


Event/Time News Detail
Loading, please wait...

BNGO Latest Social Stream


Loading social stream, please wait...

View Full BNGO Social Stream

Latest BNGO News From Around the Web

Below are the latest news stories about BIONANO GENOMICS INC that investors may wish to consider to help them evaluate BNGO as an investment opportunity.

Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research

SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its VIA™ software for applications in constitutional genetic disease. The latest analysis pipeline, Bionano Solve 3.8.1, enhances the sensitivity and specificity for structural variation (SV) detection from OGM data, which, when combined with copy number variant (CNV) analysis capabilities introduced in July

Yahoo | December 28, 2023

Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping

Key findings from prospective evaluation of 200 prenatal samples: Optical genome mapping (OGM) detected pathogenic structural variants (SVs) in 20.5% of samples (41/200); combination of chromosomal microarray analysis (CMA) and karyotyping (KT) detected pathogenic SVs in 19.5% of samples (39/200)Compared to CMA and KT combined in this prospective cohort, OGM had the following performance: Sensitivity: 97.4%Specificity: 100%Positive Predictive Value (PPV): 100%Negative Predictive Value (NPV): 99.

Yahoo | December 26, 2023

Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy Research

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow. The issue, which features guest editors Dr. Adam Smith from University of Toronto, Dr. Gordana Raca from Children’s Hospital Los Angeles, and Dr. Alexander Hoischen from Radboud University Medical Center, includes eight peer-reviewed publications, with three additional p

Yahoo | December 14, 2023

Bionano Laboratories Announces Publication of the Analytical Validation of its OGM-Based Laboratory Developed Test for Hematological Malignancies and Additional Multi-Site Technical Evaluation of OGM

SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne. This LDT is based on optical genome mapping (OGM) analysis of blood or bone marrow samples to detect structural variants (SVs) of diagnostic and prognostic utility in individuals with a new or an existing diagnosis of a hematological malignancy. The publication also included a multi-sit

Yahoo | December 12, 2023

Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting

A platform presentation will feature Dr. Enze Liu from the Indiana University School of Medicine sharing findings from a study on the use of optical genome mapping (OGM) to detect structural variants (SVs) in multiple myelomaThirteen scientific posters featuring results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and hematological malignancy research will be presented at the conference SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) --

Yahoo | December 6, 2023

Read More 'BNGO' Stories Here

BNGO Price Returns

1-mo -18.40%
3-mo -37.04%
6-mo -65.77%
1-year -90.56%
3-year -98.87%
5-year -97.69%
YTD -46.03%
2023 -87.05%
2022 -51.17%
2021 -2.92%
2020 148.39%
2019 -76.34%

Continue Researching BNGO

Want to see what other sources are saying about Bionano Genomics Inc's financials and stock price? Try the links below:

Bionano Genomics Inc (BNGO) Stock Price | Nasdaq
Bionano Genomics Inc (BNGO) Stock Quote, History and News - Yahoo Finance
Bionano Genomics Inc (BNGO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!